EDUCATION > Educational Programs > Education for APN/PA/Allied Health > Spotlight on Urologic Oncology

APN/PA Spotlight on Urologic Oncology

Urologic Oncology Educational Activity

Credit Designation: The American Urological Association Education and Research, Inc designate this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Status
Module 1 APNPA Module Posttest Available 1.00 credits/hours

Overview

In this era of increasing responsibility for primary care physicians and primary mid-level providers, it is important to recognize physical signs and symptoms that require additional evaluation and that may be a marker of urologic malignancy. Early identification of key signs and symptoms coupled with a thorough understanding of AUA practice guidelines, can lead to efficient medical evaluations and potentially to the detection of early stage urologic malignancies with a greater chance of cure. These issues are important in the detection of early prostate and bladder cancers.

Although the early detection of new tumors may be hampered by barriers to screening and inadequate diagnostic tools, the detection of recurrent tumors in patients with existing urologic malignancies may be more straightforward. The surveillance of such patients is critical to offer early salvage therapies that may still afford curative treatments. Many primary providers are unaware of the accepted surveillance practices of the major urologic malignancies, including prostate, bladder, and renal cell carcinomas.

This activity is designed to provide participants with an overview of the AUA guidelines for PSA screening and hematuria, and integrating the AUA into clinical practice, including specific time points and diagnostic tests for cancer surveillance of patients with urologic malignancies.

Learning Objectives

Upon completion of this activity participants should be able to:

  1. Identify male populations that require PSA screening, according to AUA guidelines.
  2. Formally diagnose hematuria in men and women.
  3. Interpret and explain the AUA guidelines for PSA screening and hematuria.
  4. Integrate AUA guidelines for PSA screening and hematuria into clinical practice.
  5. Define specific time points and diagnostic tests for cancer surveillance of patients with urologic malignancies.

Target Audience

  • Physician Assistants
  • Advanced Practice Nurses

Method of Participation

Learners will participate in this interactive online educational activity by reading through slides and case studies, answering multiple choice questions, examining patient tools and resources and completing the posttest and evaluation. There is no fee to participate in this CME activity. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete this activity: 1.0 hour

Release Date: May, 2014

Expiration Date: May, 2017

Software Requirements for Online Test

A PC-compatible computer running Windows XP, or a Macintosh computer running OS X 10.4 or later. Internet access. Adobe Acrobat Reader 9 or newer.

AUA Disclosure Policy

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Faculty

The content of this enduring material was compiled by Cheryl Taylore Lee, MD and reviewed by Lou Koncz, PA-C from a presentation developed and previously presented by Sam S. Chang, MD.

Faculty Disclosures

Sam S. Chang, MD: Janssen: Consultant or Advisor, Meeting Participant or Lecturer; Astellas: Consultant or Advisor; Dendreon: Consultant or Advisor; NIH: Scientific Study or Trial; Cold Genesys, Inc.: Scientific Study or Trial; Cepheid: Scientific Study or Trial

Louis Koncz, PA-C: Nothing to disclose

Cheryl Taylore Lee, MD: Adolor: Scientific Study or Trial; Tengion, Inc.: Consultant or Advisor, Scientific Study or Trial; Endo Pharmaceuticals: Consultant or Advisor, Scientific Study or Trial; Photocure: Consultant or Advisor; CVI: Consultant or Advisor

Planner Disclosures

Education Council

Christopher Lee Amling, MD: Janssen: Meeting Participant or Lecturer

Gopal Badlani, MD: Lithotripsy Group: Piedmont stone & Physician Discovery: Investment Interest; Society of University Urologist: Leadership Position; NIDDK: Leadership Position

Timothy Charles Brand, MD: Nothing to disclose

Peter Robert Carroll, MD: NIH: Scientific Study or Trial; Department of Defense: Scientific Study or Trial; Myriad Genetics: Scientific Study or Trial; Genomic Health: Scientific Study or Trial; Abbott Pharmaceuticals: Scientific Study or Trial; AUA Update: Leadership Position; Astra Zeneca: Meeting Participant or Lecturer; Genome Dx: Consultant or Advisor; Intuitive: Meeting Participant or Lecturer; Genomic Health: Consultant or Advisor; Takeda Pharmaceutical Company: Meeting Participant or Lecturer; Teva Pharmaceutical Industries: Meeting Participant or Lecturer; Janssen Pharmaceutical Companies: Meeting Participant or Lecturer; Intuitive Surgical Inc.: Meeting Participant or Lecturer

Sam S. Chang, MD: Janssen: Consultant or Advisor, Meeting Participant or Lecturer; Astellas: Consultant or Advisor; Dendreon: Consultant or Advisor; NIH: Scientific Study or Trial; Cold Genesys, Inc.: Scientific Study or Trial; Cepheid: Scientific Study or Trial

Pat Fox Fulgham, MD: Urology Clinics of North Texas: Investment Interest

Bruce R. Gilbert, MD, PhD: Bayer Healthcare Pharmaceuticals Inc.: Scientific Study or Trial; Auxilium: Scientific Study or Trial; Clarus Pharmaceutcals: Scientific Study or Trial; Eli Lilly: Scientific Study or Trial; Warner Chilcott: Scientific Study or Trial

Christina Hernandez (AUA Staff): Nothing to disclose

Douglas A. Husmann, MD: Nothing to disclose

Wes Kassouf, MD: Nothing to disclose

Louis Koncz, PA-C: Nothing to disclose

Cheryl Taylore Lee, MD: Adolor: Scientific Study or Trial; Tengion, Inc.: Consultant or Advisor, Scientific Study or Trial; Endo Pharmaceuticals: Consultant or Advisor, Scientific Study or Trial; Photocure: Consultant or Advisor; CVI: Consultant or Advisor

Thomas Sean Lendvay, MD: Spi Surgical Inc.: Consultant or Advisor, Owner, Product Development; MIMIC Technologies Inc.: Other

Vinata B. Lokeshwar, PhD: Nothing to disclose

Elspeth Marguerita McDougall, MD: Nothing to disclose

John Patrick Mulhall, MD: Association of Peyronie's Disease Advocates (APDA): Leadership Position; Pfizer: Scientific Study or Trial; Vivus: Consultant or Advisor, Scientific Study or Trial; Nexmed: Consultant or Advisor; Absorption Pharmaceuticals: Consultant or Advisor; AMS: Consultant or Advisor, Scientific Study or Trial; Meda: Consultant or Advisor; Lilly: Consultant or Advisor; Alliance for Fertility Preservation: Leadership Position

J. Kellogg Parsons, MD: AMS: Meeting Participant or Lecturer; Sophiris: Consultant or Advisor; Watson: Consultant or Advisor

Lee Richstone, MD: Wundercare LLC: Consultant or Advisor

Marianne D. Sadar, PhD: ESSA Pharma Inc.: Leadership Position, Consultant or Advisor, Investment Interest

Karl-Dietrich Sievert, MD, PhD: AMS: Meeting Participant or Lecturer; Karl Storz: Meeting Participant or Lecturer; Photocure: Scientific Study or Trial; Medtronics: Meeting Participant or Lecturer, Scientific Study or Trial; Allergen: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Neotract: Meeting Participant or Lecturer

Sheila Stark, PhD (AUA Staff): Nothing to disclose

William Donald Steers, MD: National Institutes of Health: Consultant or Advisor, Meeting Participant or Lecturer; Allergan: Scientific Study or Trial; New England Research Institute (NERI): Consultant or Advisor, Scientific Study or Trial

Chandru P. Sundaram, MD: Cook Medical Inc.: Scientific Study or Trial; North Central Section of the AUA: Leadership Position; Journal of Endourology and Videourology: Leadership Position; Society of Urological Robotic Surgeons: Leadership Position

Ashutosh Kumar Tewari, MD: Intuitive Surgical: Scientific Study or Trial; Kalyani Prostate Cancer Institute: Leadership Position; Global Prostate Cancer Foundation: Leadership Position; Peter Georgescu Foundation Award: Leadership Position; Chris Lange Foundation: Other; Peter Kalikow Foundation: Other; Craig Effron Foundation: Other; Tim O'Neill Foundation: Other; Patent for a Catheter-less device and approach: Other; NIH RO1 Funding-PI: Other

Paul Jacob Turek, MD: MandalMed: Leadership Position; Medical Board of California: Consultant or Advisor; BioQuiddity, Inc.: Consultant or Advisor, Investment Interest; HealthLoop.com: Consultant or Advisor, Investment Interest; Doximity, Inc.: Consultant or Advisor, Investment Interest; Fertility Planit, Inc.: Consultant or Advisor, Investment Interest

Alan J. Wein, MD, PHD (HON): Allergan: Consultant or Advisor, Meeting Participant or Lecturer; Medtronic: Consultant or Advisor, Meeting Participant or Lecturer; Ferring Pharmaceuticals: Consultant or Advisor, Meeting Participant or Lecturer; Pfizer; Consultant or Advisor, Meeting Participant or Lecturer; Astellas: Consultant or Advisor, Meeting Participant or Lecturer; Merck: Consultant or Advisor; opko: Consultant or Advisor; theravida: Consultant or Advisor

APN/PA Education Committee

Jeffrey A. Albaugh, PhD, APRN-BC, CUCNS: Sexual Medicine Society of North America: Leadership Position, Meeting Participant or Lecturer; Society of Urologic Nurses & Associates: Leadership Position, Meeting Participant or Lecturer; Prostate Net: Meeting Participant or Lecturer; Jannetti Publications Inc.: Other; Actient Pharmaceuticals LLC.: Consultant or Advisor, Meeting Participant or Lecturer; Astellas Pharma: Consultant or Advisor; Medivation: Consultant or Advisor

Roxelyn Baumgartner, RN, APN-BC: Nothing to disclose

Ashleigh Decker, PA-C: Nothing to disclose

Todd James Doran, MS, PA-C: Urological Association of Physician Assistants: Leadership Position; Physician Assistant Education Association: Leadership Position

Susan M. Flick, CNP: Pfizer: Other

Peggy Francis, DNP, RN, MSN, CS, FNP-BC, CUNP: Warner Chilcott: Meeting Participant or Lecturer

Gina Fries, RPA-C: Astellas Pharma US: Scientific Study or Trial

Raymond Matthew Galocy, ANP-C: Nothing to disclose

Michele Huebner, PA-C: Urological Association of Physician Assistants: Leadership Position

Louis Koncz, PA-C: Nothing to disclose

Ralph Raphael Madeb, MD: Nothing to disclose

Thomas P. McBride, PA-C: Adirondack Society of Physician Assistants: Leadership Position, Meeting Participant or Lecturer; Dendreon Corporation: Investment Interest; SeekingAlpha.com: Health Publishing

Heather Schultz, NP: Nothing to disclose

Allen D. Seftel, MD: Auxilium: Consultant or Advisor, Scientific Study or Trial; Journal of Urology: Leadership Position; Abbott: Consultant or Advisor; Lilly: Consultant or Advisor, Scientific Study or Trial; Journal of Sexual Medicine: Leadership Position; American Geriatrics Society: Leadership Position; Urology Care Foundation: Leadership Position; Mid-Atlantic Section of AUA: Leadership Position; AUA NPP committee: Leadership Position; International Journal of Impotence Research: Leadership Position; Patient Pocket, LLC: Owner, Product Development.

Meredith Vaccaro (AUA Staff): Nothing to disclose

Accreditation Statement

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American Urological Association designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

If you have already received credit for this course by attending it or watching it live you cannot receive additional credit.

Evidence-Based Content

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

Off-labeled or Unapproved Use of Drugs or Devices

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Privacy and Confidentiality Policy

www.auanet.org/education/confidentiality-statement.cfm

Contact Information

American Urological Association
Office of Education
1000 Corporate Blvd.
Linthicum, MD 21090
Toll Free (U.S. only): 1-866-RING AUA (1-866-746-4282)
Phone: 410-689-3700
Fax: 410-689-3800

CME Information

For all inquiries regarding CME credit email: cme@AUAnet.org

eLearning Activities

Case Study

January 2014 – Oncology: Renal Tumors
December 2013 – Adrenal Tumors

Other Educational Courses

AUA Annual Review Course
June 5 – 8, 2014
New Orleans, LA
*Online Webcast Option Available After Course!

In preparation of the American Board of Urology (ABU) Qualifying (Part 1) Examination residents need to have basic urologic knowledge to prepare them for the ABU examinations. To fulfill this need, the American Urological Association (AUA) developed this course to disseminate current urologic knowledge. This course may also be of interest to practicing urologists preparing for the Recertification Examination as well as others, including allied health professionals, looking for a thorough review of basic urologic topics.

AUA Basic Sciences of Urology
June 14 – 17, 2014
Charlottesville, VA

The Basic Sciences of Urology course is designed to apply basic science knowledge and principles in development of treatment algorithms. This 4-day course will provide attendees with valuable skills in developing a rational methodological approach to application of knowledge which will contribute to positive outcomes for patients. Attendees will discover the importance of the study of basic sciences and how it transfers into lifelong learning process and medical practice.

Educational Series: Advanced Prostate Cancer Care Chicago
Educational Series: Advanced Prostate Cancer Care Newark

Video's on AUA's Youtube Page

AUA Guideline Presentation: Follow-up Care for Renal Cancer
AUA Guideline Presentation: Detection of Prostate Cancer
AUA Guideline Presentation: Castration-Resistant Prostate Cancer

AUA Cancer Guidelines

Detection of Prostate Cancer Guideline

Prostate Cancer Management Guideline

Castration Resistant Prostate Cancer Guideline

Renal Cancer Guideline

Bladder Cancer Guideline

Guidelines YouTube Channel

Detection of Prostate Cancer
(viewers can obtain CME credit)

Radiation After Prostatectomy
(viewers can obtain CME credit)

Guidelines Webcast Panel Discussion Castration Resistant Prostate Cancer
(viewers can obtain CME credit)

Guidelines App

Download AUA Guidelines Apps

AUA Guidelines at a Glance
AUA Guidelines at a Glance
[ Android ]  [ Apple App Store
 
AUA Guidelines at a Glance for Primary Care Professionals
AUA Guidelines at a Glance for Primary Care Professionals
[ Android ]  [ Apple App Store
 

Toolkits

AUA's Early Detection of Prostate Cancer Toolkit

Foundation Guide

The Management of Localized Prostate Cancer Patient Guide

Algorithm

Management of Renal Cancer Algorithm

For referral to a urologist, use our Find A Urologist tool at UrologyHealth.org/FindAUrologist. Chose "incontinence" as a "special interest area" to find urologists who said they are interested in treating OAB and Incontinence.

For more information contact:
Urology Care Foundation
1000 Corporate Blvd.
Linthicum, MD 21090
1-800-828-7866
www.UrologyHealth.org

ADVERTISEMENT

ADVERTISEMENT
Donate
Contact
Press/Media
Sections
Term of Use
Site Map


ADVERTISEMENT